SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

Company Overview

SOPHiA GENETICS is a data-driven medicine company that leverages artificial intelligence and advanced analytics to enable healthcare institutions and researchers to make more informed decisions in patient care. Founded in 2011 and headquartered in Boston, Massachusetts, with key operations in Geneva, Switzerland, SOPHiA GENETICS has established itself as a pioneer in the field of genomic and radiomic data interpretation. The company’s mission is to democratize data-driven medicine by providing scalable, cloud-based solutions that address critical challenges in diagnostics and treatment planning.

The core offering of SOPHiA GENETICS is its SOPHiA DDM™ platform, which integrates next-generation sequencing (NGS) data analysis, radiomics, and digital pathology workflows. By harmonizing multimodal biomedical data, the platform delivers standardized, reproducible insights that support the detection of genetic variants, the assessment of tumor phenotypes, and the characterization of rare diseases. SOPHiA DDM™ is designed to be vendor-agnostic, enabling laboratories to seamlessly incorporate diverse sequencing technologies and imaging modalities into their diagnostic pipelines.

SOPHiA GENETICS serves a wide range of customers, including clinical laboratories, hospitals, biopharmaceutical companies, and academic research centers across North America, Europe, Asia, and Latin America. The company’s cloud-based infrastructure facilitates secure data sharing and collaboration among healthcare professionals, accelerating research programs and clinical trials. To support local needs, SOPHiA GENETICS maintains regional offices and partnerships, ensuring compliance with evolving regulatory requirements and data privacy standards.

Under the leadership of co-founder and Chief Executive Officer Jurgi Camblong, SOPHiA GENETICS has pursued strategic partnerships with leading academic institutions, diagnostic companies, and pharmaceutical firms. The management team combines expertise in genomics, bioinformatics, and clinical development to drive ongoing innovation in artificial intelligence applications. Through continuous platform enhancements and collaborations, SOPHiA GENETICS is committed to expanding the adoption of data-driven medicine and improving patient outcomes worldwide.

Key Stats

• Today's Range: $2.81 to $3.27
• 50-Day Range: $2.85 to $3.29
• 52-Week Range: $2.58 to $4.92
• Volume: 159,559 shs
• Average Volume: 59,113 shs
• Market Capitalization: $216.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

SOPHiA GENETICS Stock Analysis - MarketRank™

SOPHiA GENETICS scored higher than 47% of companies evaluated by MarketBeat, and ranked 563rd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

SOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

SOPHiA GENETICS has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.96) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SOPHiA GENETICS is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SOPHiA GENETICS is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SOPHiA GENETICS has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of SOPHiA GENETICS has been sold short.

Short Interest Ratio / Days to Cover

SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SOPHiA GENETICS has recently decreased by 37.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SOPHiA GENETICS does not currently pay a dividend.

Dividend Growth

SOPHiA GENETICS does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.04% of the float of SOPHiA GENETICS has been sold short.

Short Interest Ratio / Days to Cover

SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SOPHiA GENETICS has recently decreased by 37.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for SOPH on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.88% of the stock of SOPHiA GENETICS is held by insiders.

Percentage Held by Institutions

Only 31.59% of the stock of SOPHiA GENETICS is held by institutions.

SOPH Stock Analysis - Frequently Asked Questions

How have SOPH shares performed this year?

SOPHiA GENETICS's stock was trading at $3.07 at the start of the year. Since then, SOPH stock has increased by 5.9% and is now trading at $3.25.

How were SOPHiA GENETICS's earnings last quarter?

SOPHiA GENETICS SA (NASDAQ:SOPH) released its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.05. The company had revenue of $17.78 million for the quarter, compared to analysts' expectations of $16.76 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 63.47% and a negative net margin of 98.51%.
Read the conference call transcript.

When did SOPHiA GENETICS IPO?

SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share.

How do I buy shares of SOPHiA GENETICS?

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SOPHiA GENETICS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include Occidental Petroleum (OXY), PayPal (PYPL), Chesapeake Energy (CHK), Cheniere Energy (LNG), Rocket Pharmaceuticals (RCKT), AbCellera Biologics (ABCL) and Farmers & Merchants Bancorp (FMAO).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SOPH
• CIK: 1840706
• Web: www.sophiagenetics.com
• Phone: 41-21-694-1060
• Fax: N/A
• Employees: 520
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +115.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.49 million
• Net Margins: -98.51%
• Pretax Margin: -96.41%
• Return on Equity: -63.47%
• Return on Assets: -40.06%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 3.11
• Quick Ratio: 2.94

Sales & Book Value

• Annual Sales: $65.17 million
• Price / Sales: 3.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.48 per share
• Price / Book: 2.20

Miscellaneous

• Outstanding Shares: 66,690,000
• Free Float: 63,433,000
• Market Cap: $216.74 million
• Optionable: Not Optionable
• Beta: 1.00